|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SMIM30 |
Gene summary for SMIM30 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SMIM30 | Gene ID | 401397 |
| Gene name | small integral membrane protein 30 | |
| Gene Alias | LINC00998 | |
| Cytomap | 7q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 401397 | SMIM30 | LZE2T | Human | Esophagus | ESCC | 3.94e-07 | 5.62e-01 | 0.082 |
| 401397 | SMIM30 | LZE4T | Human | Esophagus | ESCC | 1.47e-07 | 2.42e-01 | 0.0811 |
| 401397 | SMIM30 | LZE5T | Human | Esophagus | ESCC | 8.47e-11 | 5.62e-01 | 0.0514 |
| 401397 | SMIM30 | LZE7T | Human | Esophagus | ESCC | 9.32e-08 | 3.67e-01 | 0.0667 |
| 401397 | SMIM30 | LZE8T | Human | Esophagus | ESCC | 4.82e-12 | 3.37e-01 | 0.067 |
| 401397 | SMIM30 | LZE20T | Human | Esophagus | ESCC | 4.88e-05 | 1.64e-01 | 0.0662 |
| 401397 | SMIM30 | LZE22T | Human | Esophagus | ESCC | 1.00e-09 | 5.38e-01 | 0.068 |
| 401397 | SMIM30 | LZE24T | Human | Esophagus | ESCC | 6.88e-12 | 3.17e-01 | 0.0596 |
| 401397 | SMIM30 | LZE21T | Human | Esophagus | ESCC | 1.16e-05 | 3.22e-01 | 0.0655 |
| 401397 | SMIM30 | LZE6T | Human | Esophagus | ESCC | 7.09e-15 | 5.16e-01 | 0.0845 |
| 401397 | SMIM30 | S014 | Human | Liver | HCC | 1.17e-24 | 5.72e-01 | 0.2254 |
| 401397 | SMIM30 | S015 | Human | Liver | HCC | 3.09e-24 | 6.31e-01 | 0.2375 |
| 401397 | SMIM30 | S016 | Human | Liver | HCC | 3.59e-26 | 5.98e-01 | 0.2243 |
| 401397 | SMIM30 | Pat01-B | Human | Stomach | GC | 2.99e-02 | 9.98e-02 | 0.5754 |
| 401397 | SMIM30 | Pat02-B | Human | Stomach | GC | 3.09e-28 | 4.05e-01 | 0.0368 |
| 401397 | SMIM30 | Pat03-B | Human | Stomach | GC | 5.99e-11 | 2.60e-01 | 0.3693 |
| 401397 | SMIM30 | Pat04-B | Human | Stomach | GC | 1.01e-24 | 4.87e-01 | -0.1483 |
| 401397 | SMIM30 | Pat05-B | Human | Stomach | GC | 8.26e-19 | 4.74e-01 | -0.0353 |
| 401397 | SMIM30 | Pat06-B | Human | Stomach | GC | 1.41e-28 | 4.37e-01 | -0.1961 |
| 401397 | SMIM30 | Pat07-B | Human | Stomach | GC | 5.61e-12 | 4.54e-01 | 0.0935 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |